Sotagliflozin, sold under the brand name Zynquista, Inpefa is a drug for type 1Indiabetes.
Routes of administration-By mouth
The most common side effect is genital infection in women.
Other common side effects include diabetic ketoacidosis, diarrhea and genital infection in men.
Sotagliflozin is a combination sodium/glucose cotransporter 1 and 2 (SGLT1/2) inhibitor and is in the class of drugs known as gliflozins.
Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart, failure, or type two diabetes, chronic kidney disease, and other cardiovascular risk factors.
In patients with type 2 diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events.